Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease

Gastroenterology

Volumn 149, Issue 2, 2015, Pages 389-397.e10

  Angulo, Paul ^a   Kleiner, David E ^b   Dam Larsen, Sanne ^c   Adams, Leon A ^d   Bjornsson, Einar S ^e   Charatcharoenwitthaya, Phunchai ^f   Mills, Peter R ^g   Keach, Jill C ^h   Lafferty, Heather D ^g   Stahler, Alisha ^h   Haflidadottir, Svanhildur ⁱ   Bendtsen, Flemming ^j  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Department of Clinical Biochemistry   (Denmark)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF ICELAND   (Iceland)

^f MAHIDOL UNIVERSITY   (Thailand)

^g GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^h MAYO CLINIC   (United States)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

NASH; Prediction; PRELHIN Study; Prognosis

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ARTICLE; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RETROSPECTIVE STUDY; SMOKING; SURVIVAL TIME; BIOPSY; COMPLICATION; EUROPE; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; THAILAND; TIME FACTOR; UNITED STATES;

ADULT; AGE FACTORS; BIOPSY; DIABETES MELLITUS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; THAILAND; TIME FACTORS; UNITED STATES;

EID: 84938057875     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.04.043     Document Type: Article

References (26)

1. S. Bellentani, and M. Marino Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD) Ann Hepatol 8 Suppl 1 2009 S4 S8
2. S.H. Caldwell, D.H. Oelsner, J.C. Iezzoni, and et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease Hepatology 29 1999 664 666
3. F.D. Mendes, A. Suzuki, S.O. Sanderson, and et al. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 10 2012 1028 1033
4. N. Bhala, P. Angulo, D. van der Poorten, and et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study Hepatology 54 2011 1208 1216
5. G. Baffy, E.M. Brunt, and S.H. Caldwell Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace J Hepatol 56 2012 1384 1391
6. V.G. Agopian, F.M. Kaldas, J.C. Hong, and et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic Ann Surg 256 2012 624 633
7. L.A. Adams, J.F. Lymp, J. St Sauver, and et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 2005 113 121
8. S. Dam-Larsen, U. Becker, M.B. Franzmann, and et al. Final results of a long-term, clinical follow-up in fatty liver patients Scand J Gastroenterol 44 2009 1236 1243
9. M. Ekstedt, L.E. Franzen, U.I. Mathiensen, and et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 44 2006 865 873
10. Z.M. Younossi, M. Stepanova, N. Rafiq, and et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality Hepatology 53 2011 1874 1882
11. D.E. Kleiner, E.M. Brunt, M. Van Natta, et al. Nonalcoholic Steatohepatitis Clinical Research Network Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
12. E.M. Brunt, D.E. Kleiner, L.A. Wilson, et al. NASH Clinical Research Network (CRN) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings Hepatology 53 2011 810 820
13. E.M. Brunt, D.E. Kleiner, C. Behling, and et al. Misuse of scoring systems Hepatology 54 2011 369 370
14. P. Angulo Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts Hepatology 53 2011 1792 1794
15. E.M. Brunt, D.E. Kleiner, L.A. Wilson, et al. NASH Clinical Research Network Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network Hepatology 49 2009 809 820
16. E.A. Rakha, L. Adamson, E. Bell, and et al. Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease J Clin Pathol 63 2010 790 795
17. Non-competing continuation progress report (PHS 2590). US Department of Health and Human Services Public Health Service, 2014. Available: http://grants.nih.gov/grants/funding/2590/phs2590.pdf. Accessed: March 6, 2015.
18. R. de Franchis Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension J Hepatol 53 2010 762 768
19. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
20. A.J. Sanyal, E.M. Brunt, D.E. Kleiner, and et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis Hepatology 54 2011 344 353
21. E.M. Brunt, D.E. Kleiner, L. Wilson, and et al. Histologic predictors of improvement in fibrosis in NASH: results from the Clinical Research Network PIVENS trial Hepatology 56 Suppl 2012 887A
22. P. Angulo Clinical trials: trial design in NASH - realities and challenges Nat Rev Gastroenterol Hepatol 8 2011 424 425
23. A.J. Sanyal, N. Chalasani, K.V. Kowdley, and et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
24. E.M. Brunt, P.H. Belt, L. Wilson, and et al. Progression to bridging fibrosis in non-alcoholic fatty liver disease over 4 years in the NASH CRN Hepatology 58 Suppl 2013 495A
25. D.E. Kleiner, E.M. Brunt, L. Wilson, and et al. Fibrosis progression in adult non-alcoholic fatty liver disease: association with severity of histological features Mod Pathol 27 2014 423A
26. P. Bedossa FLIP Pathology Consortium Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease Hepatology 60 2014 565 575